Tadalafil for benign prostatic hyperplasia.
Tadalafil is a phosphodiesterase type-5 (PDE5) inhibitor licensed for the treatment of erectile dysfunction (ED) in adult males (Cialis-Lilly) and for the management of pulmonary arterial hypertension (Adcirca-Lilly).(1) The 5mg tablet was licensed in November 2012 for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult males (Cialis 5mg-Lilly).(2) In this article, we consider the evidence for tadalafil and how its use fits with current management strategies for BPH.
D000328:Adult; D002243:Carbolines / Q000494:pharmacology / Q000627:therapeutic use*; D017277:Drug Approval; D007172:Erectile Dysfunction / Q000188:drug therapy; D065627:Familial Primary Pulmonary Hypertension; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D000068581:Tadalafil
D002243:Carbolines; D058986:Phosphodiesterase 5 Inhibitors; D000068581:Tadalafil